Compare Eli Lilly And Co (LLY) vs Schwab US Dividend Equity ETF (SCHD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Schwab US Dividend Equity ETF — how do they compare? Eli Lilly And Co trades at $1,177.77 (market cap $1.04T), while Schwab US Dividend Equity ETF trades at $33.03 (market cap $110.56B). The key difference: Eli Lilly And Co is far larger — about 9.4× Schwab US Dividend Equity ETF's market cap, and Eli Lilly And Co pays a 0.59% dividend while Schwab US Dividend Equity ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Schwab US Dividend Equity ETF for 62 Days on average.
| LLY | SCHD | |
|---|---|---|
Market Cap | $1.04T | $110.56B |
Volume | 3,064,878 | 23,539,168 |
Sector | Health | Broad Market / Factor |
52-Week High | $1.28K | $35.21 |
52-Week Low | $799.57 | $26.44 |
Typical Hold Time | 93 Days | 62 Days |
Enterprise Value | $1.09T | — |
Dividend Yield | 0.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,179.27, down 0.79% on the day, with a bullish technical outlook and strong fundamental momentum. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 expectation. Revenue surged to $65.18 billion in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing its market leadership.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include competitive pressures in the obesity drug market and execution challenges in scaling production. With a consensus price target of $1,350, representing ~14% upside, the stock offers growth potential but requires monitoring of pipeline progress and market dynamics.
SCHD trades at $33.04, up 1.19% today, with a bullish technical signal but mixed moving averages. The ETF focuses on high-quality U.S. dividend stocks, though key valuation ratios like P/E and P/B are not provided in the data. Recent news highlights its outperformance versus the S&P 500 in 2026 and a dividend payment scheduled for September 28, 2026.
Outlook is supported by dividend growth and defensive positioning, but risks include interest rate sensitivity and strict selection rules that may exclude high-growth stocks. Analyst sentiment is mixed, with technical indicators suggesting near-term consolidation around key support at $33.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Schwab US Dividend Equity ETF
SCHD is an ETF that tracks the Dow Jones U.S. Dividend 100 Index. It selects high-quality companies with a consistent track record of paying dividends, focusing on financial strength metrics like cash flow to total debt and return on equity, and excluding REITs. The fund aims to provide both income and capital appreciation, making it a popular choice for long-term, dividend-focused investors.
Read more on SCHD →
